IVIG-acquired hemophilia is a rare disorder where antibodies attack clotting protein factor VIII, disrupting blood clotting. Patients face puzzling symptoms and complex treatment choices. Understanding causes, signs, and therapies improves awareness and care. This condition affects roughly 1.5 per million people annually.